Related references
Note: Only part of the references are listed.Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
Jonathan W. Day et al.
BIOPOLYMERS (2012)
Targeting the glucagon receptor family for diabetes and obesity therapy
Young Min Cho et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Glucagon antagonism as a potential therapeutic target in type 2 diabetes
J. I. Bagger et al.
DIABETES OBESITY & METABOLISM (2011)
The metabolic actions of glucagon revisited
Kirk M. Habegger et al.
NATURE REVIEWS ENDOCRINOLOGY (2010)
Glucagon receptors
F. Authier et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications
Beth Elaine Dunning et al.
ENDOCRINE REVIEWS (2007)
Alpha cell function in health and disease: influence of glucagon-like peptide-1
BE Dunning et al.
DIABETOLOGIA (2005)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Differential regional metabolism of glucagon in anesthetized pigs
CF Deacon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2003)
The daily rhythm in plasma glucagon concentrations in the rat is modulated by the biological clock and by feeding behavior
M Ruiter et al.
DIABETES (2003)
Glucagon and regulation of glucose metabolism
GQ Jiang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2003)
Share Paper
